New imaging agent could predict cancer drug success
Diagnosis
Recruiting now
This early-stage study tests a new PET imaging agent, 18F-Clofarabine, to measure an enzyme (DCK) activity in metastatic cancers. The goal is to see if this scan can predict whether drugs like gemcitabine will be taken up by cancer cells. About 4 adults with metastatic cancer wil…
Phase: EARLY_PHASE1 • Sponsor: Roberto Vargas • Aim: Diagnosis
Last updated May 17, 2026 06:47 UTC